Article Information
History
- September 10, 2021.
Article Versions
- You are currently viewing Version 1 of this article (September 10, 2021 - 10:53).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Irina Kadyrova1,^,*,
- Sergey Yegorov2,3,^,*,
- Baurzhan Negmetzhanov3,
- Yevgeniya Kolesnikova1,
- Svetlana Kolesnichenko1,
- Ilya Korshukov1,
- Lyudmila Akhmaltdinova1,
- Dmitriy Vazenmiller1,
- Anar Turmukhambetova1,
- Matthew S. Miller2,
- Gonzalo Hortelano3 and
- Dmitriy Babenko1
- 1Research Centre, Karaganda Medical University, 40 Gogol St, Karaganda, 100008 Kazakhstan
- 2Michael G. DeGroote Institute for Infectious Disease Research; McMaster Immunology Research Centre; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
- 3School of Sciences and Humanities, Nazarbayev University, 53 Kabanbay Batyr Ave, Nur-Sultan, 010000, Republic of Kazakhstan
- ↵*Corresponding authors’ contact emails and phones:
ikadyrova{at}qmu.kz, +77015033730 (IK), yegorovs{at}mcmaster.ca, +1(431)277-2571 (SY)
↵^ These authors contributed equally to this work
Posted September 10, 2021.
Seroprevalence of anti-SARS-CoV-2 IgG and IgA antibodies before the launch of COVID-19 vaccination in Kazakhstan
